256 related articles for article (PubMed ID: 17652822)
1. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials.
Bast A; Haenen GR; Bruynzeel AM; Van der Vijgh WJ
Cardiovasc Toxicol; 2007; 7(2):154-9. PubMed ID: 17652822
[TBL] [Abstract][Full Text] [Related]
2. Protectors against doxorubicin-induced cardiotoxicity: flavonoids.
Bast A; Kaiserová H; den Hartog GJ; Haenen GR; van der Vijgh WJ
Cell Biol Toxicol; 2007 Jan; 23(1):39-47. PubMed ID: 17063376
[TBL] [Abstract][Full Text] [Related]
3. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
4. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
5. Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity.
van Acker FA; Boven E; Kramer K; Haenen GR; Bast A; van der Vijgh WJ
Clin Cancer Res; 2001 May; 7(5):1378-84. PubMed ID: 11350909
[TBL] [Abstract][Full Text] [Related]
6. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
7. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Langer SW; Jensen PB; Sehested M
Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
[TBL] [Abstract][Full Text] [Related]
8. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
Robert J
Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
[TBL] [Abstract][Full Text] [Related]
9. Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase.
Kaiserová H; Simůnek T; van der Vijgh WJ; Bast A; Kvasnicková E
Biochim Biophys Acta; 2007 Sep; 1772(9):1065-74. PubMed ID: 17572073
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant defense against anthracycline cardiotoxicity by metallothionein.
Kang YJ
Cardiovasc Toxicol; 2007; 7(2):95-100. PubMed ID: 17652812
[TBL] [Abstract][Full Text] [Related]
11. Genotyping the risk of anthracycline-induced cardiotoxicity.
Deng S; Wojnowski L
Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice.
Bruynzeel AM; Vormer-Bonne S; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2007 Sep; 60(4):509-14. PubMed ID: 17177067
[TBL] [Abstract][Full Text] [Related]
14. 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week.
van Acker FA; van Acker SA; Kramer K; Haenen GR; Bast A; van der Vijgh WJ
Clin Cancer Res; 2000 Apr; 6(4):1337-41. PubMed ID: 10778960
[TBL] [Abstract][Full Text] [Related]
15. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress.
Li W; Xu B; Xu J; Wu XL
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):192-7. PubMed ID: 19143757
[TBL] [Abstract][Full Text] [Related]
16. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
Robert J
Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
[TBL] [Abstract][Full Text] [Related]
17. Morphine is protective against doxorubicin-induced cardiotoxicity in rat.
Kelishomi RB; Ejtemaeemehr S; Tavangar SM; Rahimian R; Mobarakeh JI; Dehpour AR
Toxicology; 2008 Jan; 243(1-2):96-104. PubMed ID: 17988779
[TBL] [Abstract][Full Text] [Related]
18. A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity.
Ludke AR; Al-Shudiefat AA; Dhingra S; Jassal DS; Singal PK
Can J Physiol Pharmacol; 2009 Oct; 87(10):756-63. PubMed ID: 19898559
[TBL] [Abstract][Full Text] [Related]
19. Angelica sinensis: a novel adjunct to prevent doxorubicin-induced chronic cardiotoxicity.
Xin YF; Zhou GL; Shen M; Chen YX; Liu SP; Chen GC; Chen H; You ZQ; Xuan YX
Basic Clin Pharmacol Toxicol; 2007 Dec; 101(6):421-6. PubMed ID: 17971065
[TBL] [Abstract][Full Text] [Related]
20. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Jones RL
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
